Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle R Mahoney

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancerCarmen J Allegra, Allyson L Parr, Lester E Wold, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 22, 2021
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2Gina L Mazza, Molly M Petersen, Brenda Ginos, et al.
Cancer|May 12, 2017
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 12, 2021
Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2Gina L Mazza, Molly M Petersen, Brenda Ginos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66Steven R Alberts, Mark S Roh, Michelle R Mahoney, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcomaSandra P D' Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinomaTimothy J Hobday, John W Kugler, Michelle R Mahoney, et al.
Cancer|February 22, 2002
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factorJohn H Edmonson, Ivy A Petersen, Thomas C Shives, et al.
JCI Insight|June 26, 2019
RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancerOghenekevwe M Gbenedio, Caroline Bonnans, Delphine Grun, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancerCarmen J Allegra, Allyson L Parr, Lester E Wold, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 22, 2021
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2Gina L Mazza, Molly M Petersen, Brenda Ginos, et al.
Cancer|May 12, 2017
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 12, 2021
Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2Gina L Mazza, Molly M Petersen, Brenda Ginos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66Steven R Alberts, Mark S Roh, Michelle R Mahoney, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcomaSandra P D' Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinomaTimothy J Hobday, John W Kugler, Michelle R Mahoney, et al.
Cancer|February 22, 2002
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factorJohn H Edmonson, Ivy A Petersen, Thomas C Shives, et al.
JCI Insight|June 26, 2019
RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancerOghenekevwe M Gbenedio, Caroline Bonnans, Delphine Grun, et al.
Pageof 5